Introduction
Messenger (m)RNA-based gene transfer, as compared to plasmid DNA and viral vectors, has several advantages when thinking in terms of clinical applications. 1 Since there is no danger of insertional mutagenesis and/or vector-induced immunogenicity, 2, 3 in vitro/ex vivo manipulation of cells with mRNA is considered to be a valuable and safe alternative when cells need to be administered to patients. One drawback of mRNA-based gene transfer is that transgene expression is only transient. However, this should not be a problem because several applications require only a short term expression of a desired transgene. This has previously been demonstrated in many studies on the use of mRNA-loaded dendritic cells for immunotherapeutic purposes. [4] [5] [6] However, many more cell types and applications might benefit from an efficient mRNAbased gene transfer method. 5 We therefore examined the potential of mRNA electroporation as a nonviral non-DNA gene transfer tool for gene expression in adult stem cells, both hematopoietic and mesenchymal, and in activated T cells. Based on the expression of an enhanced green fluorescent reporter protein (EGFP), gene transfer efficiencies are described and potential applications discussed.
Materials and methods

Source of peripheral blood and bone marrow samples
Peripheral blood was obtained from hemochromatosis patients after informed consent or from buffy coats provided by the Antwerp Blood Transfusion Center. Bone marrow samples were provided by the Hematology Clinic of the Antwerp University Hospital after informed consent. Mononuclear cells from peripheral blood and bone marrow samples were isolated by Ficoll-Hypaque gradient separation (LSM, ICN Biomedicals). Isolated cells were directly used for electroporation experiments or cultured in vitro to obtain the desired cell type before electroporation experiments.
In vitro culture of human mesenchymal cells
Mononuclear bone marrow cells were plated in T75 culture flasks in complete medium consisting of Iscove's modified Dulbecco's medium supplemented with 2 mM L-glutamine (IMDM; Invitrogen), 100 U/ml penicillin (Invitrogen), 100 mg/ml streptomycin (Invitrogen), 1.25 mg/ml amphotericin B (Invitrogen) and 10% fetal calf serum (FCS; Sera Lab). After 48 h of culture, nonadherent cells were removed, and cells were further cultured in complete medium with 10% FCS until confluent. Flow cytometric phenotyping of in vitro cultured mesenchymal cells was performed using monoclonal antibodies directed against CD45 (in PerCP) and CD13 (in PE) (both from Becton Dickinson) on a FACScan analytical flow cytometer (Becton Dickinson). In vitro cultured mesenchymal cells were characterized as CD45 negative and CD13 positive. 7 
Phytohemagglutinin stimulation of T cells
For the generation of phytohemagglutinin (PHA)-stimulated T-cell cultures, 20 Â 10 6 nonadherent PBMC were cultured in T25 culture flasks in AIM-V medium (Invitrogen) supplemented with 10% human AB serum (ICN Biomedicals) and 1 mg/ml PHA (Sigma). Cells were used for electroporation experiments after 72 h of stimulation. During flow cytometry analysis, T cells were stained with the monoclonal antibodies directed against CD2 (in PE), CD3 (in PerCP), CD4 (in PE) or CD8 (in PE) (all from Becton Dickinson).
Generation of Epstein-Barr virus-transformed B lymphoblastoid cell lines and Epstein-Barr virus-specific autologous T-cell lines B lymphoblastoid cell lines (B-LCL) were generated by infection of PBMC with the supernatant of the Epstein-Barr virus (EBV)-producing B95-8 monkey cell line 8 (kindly provided by Professor Christine Van Broeckhoven, University of Antwerp, Belgium). Cell lines were cultured in IMDM supplemented with 10% FCS. Polyclonal EBV-specific autologous T-cell lines were generated as reported by Savoldo et al. 9 Briefly, PBMC were stimulated with irradiated autologous B-LCL at an effector/ stimulator (E:S) ratio of 40:1 in IMDM supplemented with 10% FCS. Stimulated T-cells were used for electroporation experiments after 3 days of coculture or further expanded to culture EBV-specific T-cell lines. For the latter, cells were restimulated at day 10 with irradiated B-LCL (E:S ratio 4:1). From this point on, 40 U/ml recombinant human interleukin (IL)-2 (Biosource) was added to the cultures biweekly. On day 20, cultured EBVspecific T-cells were restimulated again with irradiated B-LCL (E:S ratio 4:1) and used 3 days thereafter for electroporation experiments. During flow cytometry analysis, T cells were stained with monoclonal antibodies directed against CD4 (in PE) or CD8 (in PE) (Becton Dickinson).
Electroporation of EGFP mRNA
mRNA encoding the EGFP was prepared from the pGEM4Z/ EGFP/A64 vector 10 (kindly provided by Dr Eli Gilboa, Duke University Medical Center, Durham, NC, USA) as previously described. 11 Prior to electroporation, cells were washed twice with Optimix Washing Solution (EquiBio) and resuspended to a final concentration of 50 Â 10 6 cells/ml in Optimix electroporation buffer (EquiBio). Subsequently, 0.2 ml of the cell suspension was mixed with 20 mg of in vitro transcribed EGFP mRNA and electroporated in a 0.4-cm cuvette (EquiBio) at 300 V and 150 mF using an Easyject Plus device (EquiBio). After electroporation, fresh complete medium was added to the cell suspension and cells were further cultured until flow cytometry analysis.
EGFP and cell viability analysis by flow cytometry
For flow cytometry analysis, cells were harvested, stained with appropriate monoclonal antibodies and resuspended in 500 ml of PBS (Invitrogen). To assess cell viability, ethidiumbromide (Sigma) was added to the cells (10 ml of a 20 mg/ml stock solution per 500 ml of cell suspension) prior to flow cytometry analysis. In order to exclude dead cells from the flow cytometry analysis, gating was performed on ethidiumbromide negative cells. Nonor mock-electroporated cells were used as control cells for EGFP analysis.
Results
Efficiency of mRNA electroporation in adult stem cells
Two adult bone marrow samples were electroporated with EGFP mRNA, as described in Materials and methods, and analyzed for EGFP expression after 24 h of culture. Flow cytometry analysis showed that gene transfer efficiency in the total population of fresh bone marrow cells is 25-30% (Figure 1a , histogram overlay). Moreover, the electroporation procedure did not induce significant T-cell mortality among electroporated cells (Figure 1a , dot plot). Electroporated bone marrow samples were also stained for CD34 (Figure 1b, dot plot) , and further analysis revealed that 35% of the hematopoietic progenitor cell fraction (CD34 þ cells, n ¼ 2) within adult bone marrow was efficiently electroporated with EGFP mRNA (Figure 1b, histogram overlay) .
We also tried EGFP mRNA electroporation as a non-viral method to express a transgene in mesenchymal (stem) cells. For this, bone marrow-derived mesenchymal cells from three different donors were cultured as described in Materials and methods. Expanded mesenchymal cells were characterized by flow cytometry analysis based on negative staining for CD45 and positive staining for CD13 (Figure 1c 
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Efficiency of mRNA electroporation in activated T cells
To investigate the efficiency of mRNA-electroporation in T cells, nonstimulated and PHA-stimulated PBMC were electroporated with EGFP mRNA as described in Materials and methods, and analyzed for T-cell markers (CD3 vs CD4 or CD8) and EGFP expression after 24 h of culture (Figure 2a) . Flow cytometry analysis showed that RNA-based gene transfer in nonstimulated T cells is very inefficient (Figure 2a: NO STIMULATION 
In contrast, efficiency of mRNA electroporation was very high in PHA-stimulated T cells ( Figure 2a :
Furthermore, kinetics of EGFP expression in the CD2-positive viable PHA-stimulated T-cell population was followed by flow cytometry during a period of seven days (Figure 2b ). Although the mean fluorescence intensity (MFI) of the EGFP þ cells started to decrease at day 2 after electroporation, EGFP expression could still be detected in 57719% (n ¼ 4) of viable CD2-positive T cells at 4 days after electroporation. Considering cell viability, no significant difference was observed at 24 h after electroporation in nonelectroporated (8774%, n ¼ 4) vs EGFP mRNA-electroporated T cells (8772%, n ¼ 4). Next, we investigated the efficiency of mRNA electroporation in PBMC stimulated with an EBV-transformed autologous B-cell line (B-LCL). After 3 days of in vitro coculture, as described in Materials and methods, stimulated PBMC were electroporated with EGFP mRNA and analyzed for T-cell markers (CD4 or CD8) and EGFP expression after 24 h of culture (Figure 2c 
Discussion
Gene therapy strategies used in clinical applications should be carefully developed in order to avoid serious adverse effects possibly caused by the use of plasmid DNA and viral vectors. 2, 3 Gene transfer by plasmid DNA generally does not result in high numbers of transfected cells 12 and is often associated with high cell mortality among transfected cells. The use of viral vectors for gene transfer can circumvent these problems, but their potential immunogenicity might cause serious problems. 13, 14 Moreover, for both plasmid DNA transfer and viral gene transfer, integration of DNA fragments into or next to certain genes might occur, possibly resulting in undesired gene expression following use in vivo. In contrast, the use of mRNA for transfection of cell lines and primary cells is likely to be a safe, highly efficient and clinically applicable alternative to virus and/or plasmid DNAmediated gene transfer. 1 However, since transgene expression is only transient, the potential applications are limited to gene therapy strategies where no long-term gene-expression is required. Although most of the currently ongoing gene therapy research requires stable transgene expression, 13 ,15 several applications are arising where the use of mRNA will be preferable over the use of plasmid DNA and viral vectors. This has previously been demonstrated in many studies on the use of mRNA-loaded dendritic cells for immunotherapeutic purposes, 6, 11, 16 where gene transfer by means of mRNA has become one of the most promising candidates for use in clinical trials. 1, 5 Based on this success of mRNA-mediated gene transfer, novel applications are being explored.
Recently, both hematopoietic and mesenchymal stem cells have become of major interest for the development of cell replacement therapies. 17, 18 Efficient short-term transgene expression of specific genes, growth factors or transcription factors in CD34 þ progenitor cells might be interesting to promote growth of undifferentiated progenitor cells or to (re)direct their differentiation towards a specific lineage. 19, 20 Multiple combinations of growth factors and chemicals have been described to differentiate mesenchymal cells into several different lineages of mesodermal origin, such as cartilage, bone, fat, tendon, muscle, myocardium and marrow stroma. 18 More recently, strategies using gene-modified mesenchymal cells, by means of viral transduction, have been developed for differentiation of osteogenic cells. 21, 22 Using the presented mRNA electroporation method, adult stem cells can be loaded with mRNA encoding a specific transcription factor, combinations of several transcription factors or even total mRNA fractions derived from specific cell types. It will be interesting to see whether these stem cells, after one or multiple mRNA electroporations, will be directed towards a specific lineage.
Previously published manuscripts already reported the inefficiency of plasmid DNA-based gene transfer in nonstimulated T cells, while enhanced efficiency of plasmid DNA transfection was shown in PHA-stimulated human T cells and activated CD4 þ murine T cells (32 and 34% respectively). 23, 24 Our results also show inefficient gene transfer by means of mRNA electroporation in nonstimulated T cells, while PHA-stimulated T cells can be efficiently loaded with mRNA ( Figure 2a , around 50% for both CD4 þ and CD8 þ T cells). Moreover, transgene expression could also be detected in EGFP mRNA-electroporated EBV-stimulated T cells. Thinking in terms of clinical applications, and if short-term transgene expression is sufficient, the use of mRNA instead of plasmid DNA or viral vectors would be preferable. Applications for mRNA-based gene transfer in T cells can be found in the field of adoptive T-cell immunotherapy. Introduction of telomerase in order to increase the replicative lifespan of cloned antigen-specific T cells has been reported with the use of viral vectors. 25, 26 Safety issues associated with the use of viral vectors can be circumvented by using mRNA for gene transfer. Also, directing or redirecting T-cell subtype differentiation by short-term introduction of mRNA encoding specific activating/inhibitory master regulatory genes 27 might become an interesting research direction in fundamental research towards adoptive T-cell immunotherapy, both for immune stimulation and immune tolerance.
Based on the presented results and the potential applications, we conclude that, for several applications in both fundamental research and the treatment of hematologic and other diseases, mRNA electroporation might become an important tool for gene transfer in adult stem cells and activated T cells. Moreover, using the same electroporation procedure, it can be further investigated whether a combined electroporation of mRNA, in order to express specific genes, and siRNA, in order to shut down specific genes, might be beneficial for directing (stem) cell fate in vitro and in vivo.
